Danesh Alam Selected Research

3,3'- di- (N- cyclopropylmethyl- 4,5- epoxy- 14- hydroxymorphinan- 6- one- 3- yl)carbonate

1/2020

Transition of Patients with Opioid Use Disorder from Buprenorphine to Extended-Release Naltrexone: A Randomized Clinical Trial Assessing Two Transition Regimens.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Danesh Alam Research Topics

Disease

3	Substance Withdrawal Syndrome (Withdrawal Symptoms) 01/2020 - 05/2019
2	Bradycardia 01/2020 - 05/2019
2	Hypotension (Low Blood Pressure) 01/2020 - 05/2019
1	Opioid-Related Disorders (Opiate Addiction) 01/2020
1	Orthostatic Hypotension (Postural Hypotension) 05/2019

Drug/Important Bio-Agent (IBA)

2	Opioid Analgesics (Opioids)IBA 01/2020 - 01/2020
2	lofexidineIBA 01/2020 - 05/2019
1	Naltrexone (ReVia)FDA LinkGeneric 01/2020
1	3,3'- di- (N- cyclopropylmethyl- 4,5- epoxy- 14- hydroxymorphinan- 6- one- 3- yl)carbonateIBA 01/2020
1	Buprenorphine (Subutex)FDA LinkGeneric 01/2020
1	Opiate AlkaloidsIBA 05/2019